Articles tagged with Crohn Disease
Researchers at University of Gothenburg have identified a critical mechanism to slow down Crohn's disease progression by repairing the protective barrier of the gut. By reinforcing the gut's natural defenses, new drug targets may be developed to treat the disease.
Researchers at TUM have developed a new therapeutic approach combining dietary therapy with fecal microbiome transfer to sustain inflammation-free states in Crohn's disease patients. The study found that the gut microbiome changes as a result of dietary therapy contribute to treatment success.
A new study published in the Journal of Crohn's and Colitis reveals that vancomycin may be an effective treatment for people with inflammatory bowel disease (IBD) and autoimmune liver disease. The antibiotic achieved clinical remission in 80% of patients, with significant decreases in inflammatory markers and mucosal healing.
Crohn's & Colitis Congress showcases cutting-edge research on IBD treatment barriers, genetic factors, and cardiovascular safety. Key studies reveal significant financial sacrifices made by patients to access care and identify epigenetic clues for Crohn's disease development.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
Researchers at Uppsala University found that people with psoriasis have invisible inflammation in their small intestine, which can lead to gastrointestinal problems and an increased risk of developing Crohn's disease. Half of the study participants had a leaky gut, allowing bacteria and harmful substances to leak through the intestinal...
Early treatment with TNF inhibitors has been shown to prevent complications in kids with Crohn's disease, reducing the risk of perianal fistulas by 82%. The study found that anti-TNF drugs are specifically effective in preventing these debilitating complications, making them a recommended first-line therapy.
A study by Michigan Medicine researchers suggests that sulfur-producing bacteria may be behind lingering Crohn's disease symptoms, even in the absence of inflammation. The study found that these bacteria can lead to increased visceral hypersensitivity and altered intestinal permeability, contributing to persistent symptoms.
Research highlights the critical link between the body's circadian clock and inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis. Disruptions in circadian rhythms exacerbate inflammation, suggesting that aligning treatment strategies with natural biological cycles could improve patient outcomes.
Researchers have reviewed the therapeutic potential of extracellular vesicles derived from mesenchymal stem cells in treating inflammatory bowel disease. The study highlights the immunomodulatory, pro-regenerative, and anti-apoptotic properties of these vesicles, which may offer a safer alternative to conventional therapies.
A comprehensive analysis of pediatric IBD prevalence in the US reveals an increase of 22% for Crohn's disease and 29% for ulcerative colitis in the pediatric population. The study provides crucial data to inform healthcare policy, resource allocation, and future research priorities.
Researchers identify biomarker Ki67 that indicates whether treatment with vedolizumab will be successful. The biomarker can help predict which patients are more likely to respond to the form of treatment, allowing for more targeted use and potentially improving patient outcomes.
A team of researchers, including Binghamton University's Ahyeon Koh, is working on an innovative project to treat inflammatory bowel diseases like Crohn's and ulcerative colitis. The goal is to create a 'cell factory' in the body that can produce pharmaceuticals to alleviate symptoms.
Researchers from UT Arlington sequenced RNA genes of pythons, discovering conserved pathways in humans that are activated uniquely by these snakes. This knowledge helps explain intestinal regeneration and metabolism changes, offering potential therapeutic targets.
A new study found that children diagnosed with IBD before the age of six show biological changes associated with the disease at birth. This suggests that these children are part of a severely affected subgroup, making preventive options crucial for their investigation. The study's findings could lead to earlier screening and potentiall...
Researchers at TUM found that mitochondrial dysfunction in mice leads to chronic intestinal inflammation and changes in the gut microbiome. The study suggests potential new treatments targeting mitochondrial pathways or addressing the connections between the microbiome and mitochondria.
A recent survey by the Crohn's & Colitis Foundation found that over 40% of IBD patients have made substantial financial trade-offs to access their care. Among these respondents, 22% increased their credit card debt, while 21% cut back on essential items like food and clothing.
Researchers at University of California - San Diego have discovered that Crohn's disease consists of two distinct molecular subtypes, each exhibiting unique patterns of genetic mutation and cellular phenotypes. This finding could lead to more effective management strategies, with therapies tailored to specific subtypes.
Associate Professor Justine Tigno-Aranjuez received a $1 million NSF CAREER Award to study the impact of the NOD2 pathway on inflammation. Her research aims to understand how lipid mediators are produced and how they influence inflammation.
Established biomarkers such as CRP, ESR, vitamin D, and platelets continue to be vital in IBD management. Novel biomarkers like MAdCAM-1, oncostatin M, NOD2 mutations, and anti-Integrin αvβ6 offer promise for improving diagnostic accuracy and predicting treatment response.
A new study published in Science Advances has found that antibiotics disrupt the protective mucus layer in the intestine, increasing the risk of inflammatory bowel disease. Researchers discovered that antibiotics damage the mucus barrier in a microbiota-independent manner, facilitating bacterial penetration and gut inflammation.
Researchers explore fecal calprotectin and C-reactive protein as biomarkers for inflammatory bowel diseases (IBD), with multi-target tools showing promising results. These biomarkers hold potential for improving diagnostic accuracy and monitoring disease activity, leading to more effective IBD management.
A newly developed granzyme B PET imaging method can non-invasively detect IBD and provide a real-time picture of active inflammation. This technology could guide personalized patient management strategies and monitor treatment efficacy.
Research by a University of Virginia undergraduate may help explain recurrent Crohn’s disease in children and open the door to new ways to treat or even cure the devastating condition. Children with relapsing Crohn’s had persistent disruptions of their microbiomes even after inflammation was successfully controlled.
Researchers have successfully grown 'mini-guts' in the lab to better understand Crohn's disease. The organoids show that epigenetic changes play an important role in the disease and its severity, enabling potential personalized treatments. This breakthrough could lead to more precise and effective treatments for patients.
A groundbreaking IBD study aims to identify biomarkers for personalized treatment, monitoring, and prediction. Researchers will collect genomic data from 1,000 newly diagnosed patients in the UK over four years.
A study by Mount Sinai researchers has identified several pathophysiological mechanisms underlying perianal fistulae in Crohn’s disease. The findings highlight key transcription factor binding events and epigenetic phenomena that contribute to the higher rates of complications in African American patients. The research provides avenues...
Researchers revealed the biological mechanisms by which class II HDACs activate Th17 cell differentiation, leading to inflammation. A potent inhibitor, TMP269, was found to influence Th17 cell differentiation in a mouse model of ulcerative colitis, providing potential therapeutic approach for IBD treatment.
Researchers discovered that gut bacteria can dynamically reprogram gene expression based on local conditions like inflammation or viral attacks. This adaptation strategy may worsen disease by crippling production of molecules that regulate the immune system and attenuate gut inflammation.
A new testing protocol combining clinical history with multiple home stool tests could significantly speed up diagnosis of inflammatory bowel disease (IBD) by reducing the need for unnecessary colonoscopies. Serial faecal calprotectin tests were found to strongly predict possible IBD, Crohn's Disease, and Ulcerative Colitis.
Researchers found a link between low fiber diets, mucin-degrading bacteria, and increased inflammation in mice with IBD genetics. A high-fiber diet prevented inflammation and even reversed symptoms in some cases.
A Northwestern University team developed a wireless, implantable temperature sensor to monitor inflammatory flareups in patients with Crohn's disease. This allows clinicians to act earlier to prevent permanent damage caused by inflammatory episodes.
Researchers discover that certain bacteria can evade the immune system by circumventing antibody coating, leading to severe inflammation. The study identifies IgG2 as a key player in this process, providing potential biomarkers and targets for new treatments.
The American Gastroenterological Association has proposed a 12-point plan to enhance IBD care in the US, focusing on insurer-mandated barriers such as prior authorization and step therapy. The plan aims to improve treatment access and quality for over three million Americans living with IBD.
A large-scale clinical trial has shown that offering early advanced therapy to newly-diagnosed Crohn's patients can drastically improve outcomes, including reducing the need for urgent abdominal surgery. The 'top-down' treatment strategy, which involves providing infliximab as soon as possible after diagnosis, resulted in significantly...
A study of over 80,000 children found that high fish and vegetable intakes early in life are associated with a lower risk of inflammatory bowel disease. High sugar beverage intake, on the other hand, was linked to a higher risk.
The Icahn School of Medicine at Mount Sinai will investigate the pre-disease phase of Crohn's disease, identifying unique biomarkers to predict and prevent its development. The $4 million grant aims to transform healthcare by focusing on early intervention and prevention strategies.
Researchers from Scripps Research have developed a small molecule that blocks the activity of SLC15A4, a protein linked to autoimmune diseases like lupus and Crohn's disease. The compound, FFF-21, successfully reduced inflammation in mouse models and isolated cells from people with lupus.
A new consortium, co-led by Florian Rieder, MD, and Vipul Jairath, MD, will create clinical care pathways toward drug development and improve disease management for patients with Crohn's disease and permanent ileostomy. The EndO-trial Consortium aims to develop effective drugs and measure treatment outcomes using patient-reported outco...
Researchers found IBD manifests differently among various racial groups and immigration statuses. Genetic and environmental factors contribute to varying disease courses and symptoms.
The AGA releases its first comprehensive evidence-based guideline for managing pouchitis, a complication of ulcerative colitis surgery. The guideline recommends treatment with antibiotics and multi-strain probiotics to prevent recurrent pouchitis.
A team of Kyoto University researchers found that macrophages produce granulomas through a hyperactive metabolic pathway called the pentose phosphate pathway. Inhibition of this pathway showed therapeutic efficacy in reducing granuloma formation in vitro and in mouse tissue models.
Scientists at University of California San Diego develop a new approach to microbiome research, identifying hundreds of molecules never seen before in the human body. They found a strong association between these molecules and inflammatory bowel disease, potentially leading to new diagnostic and therapeutic applications.
Researchers have developed a new method, SECRE, to identify genetic regulators of cytokine secretion in autoimmune diseases. The technique has been validated on cells known to play a crucial role in inflammatory bowel disease (IBD) and shows promising results for treating conditions with few therapeutic options.
The American Gastroenterological Association released a new guideline recommending the use of biomarkers to help manage Crohn’s disease. Biomarkers such as C-reactive protein and fecal calprotectin can measure levels of inflammation, helping doctors assess disease activity and guide treatment decisions.
Researchers found that rare gene variants associated with inflammatory bowel disease (IBD) are less prevalent in African Americans, suggesting a different genetic contribution to the disease. The study highlights the importance of considering genetic diversity and admixture in IBD research.
A study published in mSystems found that mice fed a broccoli sprout diet had milder disease symptoms and richer gut microbial communities compared to those not exposed. The researchers suggest that broccoli sprouts could be used as a treatment strategy for patients with IBD.
Researchers discovered subtle changes in minerals, cells, and inflammation markers in people with inflammatory bowel disease up to 8 years before diagnosis. These findings suggest an opportunity for preventative action or early treatment to improve quality of life.
Research at the University of Gothenburg found that even low-active IBD patients have a higher risk of serious infections due to microscopic intestinal inflammation. Achieving a fully healed intestinal mucosa may reduce this risk, contributing to lower morbidity and mortality in IBD patients.
A new study from the University of Pennsylvania School of Medicine found a significant link between inflammatory bowel disease (IBD) and atopic dermatitis (AD), with adults having a 34% increased risk and children having a 44% increased risk. The severity of AD was also associated with an increased risk of developing IBD.
Researchers have characterised a specialised type of immune cell that plays a key role in protecting and repairing the healthy human gut. Depletion of these cells is linked to inflammatory bowel disease (IBD) progression, with potential implications for treatment options.
Researchers have developed a less invasive test for inflammatory bowel disease by analyzing the sugar molecules attached to antibodies. The study found distinct patterns of glycans on immunoglobulin A (IgA) antibodies between patients with Crohn's disease and ulcerative colitis, which could lead to a simple blood-based diagnostic test.
A study published in eBioMedicine identified the mechanism behind rapid vaccine waning in patients on TNF-α blockers for autoimmune diseases like Crohn's and rheumatoid arthritis. Regular booster vaccinations are crucial to maintain protection, especially for those receiving immunosuppressive therapy.
Researchers at Karolinska Institutet found that statin treatment was associated with a lower risk of developing and dying from colorectal cancer in patients with ulcerative colitis. After a follow-up period of 5.6 years, the study showed that 70 statin users had been diagnosed with colorectal cancer compared to 90 non-statin users.
A radiomic-based model using T2-weighted MRI data achieved high accuracy in diagnosing pediatric Crohn disease, outperforming expert radiologists. The model was ensembled with clinical data to further improve performance.
Researchers developed nanoparticles that mimic the glycocalyx pattern to treat inflammatory bowel disease. The treatment reduced symptoms and inflammation in mice with IBD, with specific versions showing significant improvement.
Researchers have developed a microgel delivery system that keeps beneficial bacteria safe while actively clearing out harmful ones in the gut. In mice, this system treated intestinal inflammation without side effects and showed promise as a viable treatment strategy for intestinal diseases.
Research by West Virginia University professor Sean Tu found that orphan drugs earn pharmaceutical companies almost as much as those marketed to the general public. The Orphan Drug Act incentivizes companies with tax credits, longer patent exclusivity, and easier FDA review for treating rare diseases.
A new study suggests that high-sugar diets can exacerbate inflammatory bowel disease (IBD) symptoms by disrupting the colon's lining renewal process. The research found that a high-sugar diet led to impaired cell division and altered metabolic pathways in mice, resulting in faster gut damage.
Researchers developed human calprotectin ligands based on peptides to detect and quantify the protein in stool samples or serum levels, offering a more accurate and controlled way of detecting biomarkers.